PYC Therapeutics (PYCX.F) Stock Overview

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. More details

PYCX.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 89.8% below our estimate of its fair value

Earnings are forecast to grow 24.79% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

PYCX.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

PYC Therapeutics Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for PYC Therapeutics
Historical stock prices
Current Share Price	AU$0.85
52 Week High	AU$0.90
52 Week Low	AU$0.67
Beta	0.64
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.49%

Recent updates

Shareholder Returns

	PYCX.F	US Biotechs	US Market
7D	0%	0.4%	-1.5%
1Y	n/a	-0.7%	14.4%

Return vs Industry: Insufficient data to determine how PYCX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PYCX.F performed against the US Market.

Price Volatility

Is PYCX.F's price volatile compared to industry and market?
PYCX.F volatility
PYCX.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.5%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: PYCX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PYCX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Rohan Hockings	pyctx.com

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYCX.F fundamental statistics
Market cap	US$484.13m
Earnings (TTM)	-US$32.62m
Revenue (TTM)	US$15.24m

31.8x

P/S Ratio

-14.8x

P/E Ratio

Is PYCX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYCX.F income statement (TTM)
Revenue	AU$23.49m
Cost of Revenue	AU$0
Gross Profit	AU$23.49m
Other Expenses	AU$73.80m
Earnings	-AU$50.30m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.086
Gross Margin	100.00%
Net Profit Margin	-214.11%
Debt/Equity Ratio	0%

How did PYCX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/17 00:39
End of Day Share Price	2025/08/13 00:00
Earnings	2025/06/30
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PYC Therapeutics Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Melissa Benson	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter
David Martin	Bloom Burton & Co.

PYC Therapeutics LimitedOTCPK:PYCX.F Stock Report